In the American College of Medical Toxicology’s North American Snake Bite Registry, a prospective case registry of snake envenomed patients, 373 patients were treated with CroFab over a 3 year period (2013–2015).3
1. CroFab® [prescribing Information]. BTG International Inc; May 2017. 2. Schaeffer TH, Khatri V, Reifler LM, Lavonas EJ. Incidence of immediate hypersensitivity reaction and serum sickness following administration of crotalidae polyvalent immune fab antivenom: A meta-analysis. Acad Emerg Med. 2012;19:121-131. 3. Ruha AM, Kleinschmidt KC, Greene S, et al. The epidemiology, clinical course, and management of snakebites in the North American Snakebite Registry. J Med Toxicol. 2017;13(4):309-320. 4. Lavonas EJ, Kokko J, Schaeffer TH, Mlynarchek SL, Bogdan GM, Dart RC. Short-term outcomes after Fab antivenom therapy for severe crotaline snakebite. Ann Emerg Med. 2011;57(2):128-137.e3.